Core Viewpoint - The company, Akeso Inc. (09939), experienced a stock price increase of over 3% during trading, closing at HKD 2.16 with a trading volume of HKD 8.0645 million, following the announcement of positive results from its Phase II clinical trial for the acne treatment compound GT20029 [1]. Group 1: Clinical Trial Results - The Phase II clinical trial for GT20029, a novel targeted androgen receptor (AR) protein degradation compound, successfully met its primary endpoint with statistically significant and clinically meaningful results [1]. - The efficacy, safety, and pharmacokinetic characteristics of GT20029 were reported to be excellent, with a recommended dosage for the Phase III clinical trial set at 0.5% [1]. - The trial was a multicenter, randomized, double-blind, placebo-controlled study conducted at 10 centers nationwide, led by Professor Xiang Leihong from Huashan Hospital affiliated with Fudan University [1].
港股异动 开拓药业-B(09939)盘中涨超3% GT20029凝胶治疗痤疮II期临床试验达到主要终点